نتایج جستجو برای: capecitabine

تعداد نتایج: 4646  

Journal: :Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2016
Nobuya Kobashi Hiroki Matsumoto Songji Zhao Shunsuke Meike Yuki Okumura Tsutomu Abe Hiromichi Akizawa Kazue Ohkura Ken-Ichi Nishijima Nagara Tamaki Yuji Kuge

UNLABELLED Recently, companion diagnostics with nuclear medicine techniques have been anticipated as more suitable means than biopsy for predicting treatment efficacy. The anticancer effect of capecitabine, an orally administered chemotherapeutic agent activated by thymidine phosphorylase (TP), is positively associated with tumor TP expression levels. This study aimed to assess whether TP imagi...

Journal: :In vivo 2005
Yasuhiro Kodera Michitaka Fujiwara Hiroyuki Yokoyama Norifumi Ohashi Shinichi Miura Yuichi Ito Masahiko Koike Katsuki Ito Akimasa Nakao

BACKGROUND The synergistic antitumor effect of a combination of docetaxel and capecitabine is reported to be attributable to docetaxel-mediated up-regulation of thymidine phosphorylase (dThdPase). MATERIALS AND METHODS Intravenous docetaxel (15 mg/kg) was given to nude mice bearing xenografts of the gastric cancer cell lines MKN45 and MKN28. Mice were sacrificed on days 7, 10 and 22 and tumor...

2015
Manuela Terranova-Barberio Elena DI Gennaro Maria Serena Roca Alfredo Budillon

Capecitabine, commonly used in different settings for metastatic breast cancer, is an inactive prodrug that take advantage of the tumor elevated levels of thymidine phosphorylase (TP), a key enzyme for its conversion to 5-florouracil. Potentiation of anticancer activity of capecitabine is required to improve its therapeutic index. We demonstrated that histone deacetylase inhibitors (HDACi), inc...

2009
Mevlüt KURT Sercan AKSOY Mutlu HAYRAN İbrahim GÜLLÜ Nilüfer GÜLER

The aim of this study was to evaluate the efficacy and the toxicity of capecitabine therapy in metastatic breast cancer. A total of 103 patients treated between December 2001 and December 2005 were evaluated retrospectively. Capecitabine was used at a dose of 2500 mg/m/day for 14 days, with 3 weeks of intervals between cyclesevery 3 weeks. There were 20 patients (19.4%) with brain metastasis at...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2006
M Koopman N F Antonini J Douma J Wals A H Honkoop F L G Erdkamp R S de Jong C J Rodenburg G Vreugdenhil J M Akkermans-Vogelaar C J A Punt

BACKGROUND Results on overall survival in randomised studies of mono- versus combination chemotherapy in advanced colorectal cancer patients may have been biased by an imbalance in salvage treatments. This is the first randomised study that evaluates sequential versus combination chemotherapy with a fluoropyrimidine, irinotecan and oxaliplatin. PATIENTS AND METHODS A total of 820 patients wer...

2009
Muhammad Wasif Saif

Capecitabine is currently the only novel, orally home-administered fluorouracil prodrug. It offers patients more freedom from hospital visits and less inconvenience and complications associated with infusion devices. The drug has been extensively studied in large clinical trials in many solid tumors, including breast cancer, colorectal cancer, gastric cancer, and many others. Furthermore, the d...

Journal: :Anticancer research 2016
Chun-Ru Chien William Tzu-Liang Chen Hwei-Min Wang Tao-Wei Ke Hua-Che Chiang Sheng-Chi Chang Yu-Chun Huang Che-Hung Lin Chun-Lin Huang Ying-Chun Lin Tsung-Wei Chen Chia-Chin Li K S Clifford Chao

BACKGROUND/AIM Capecitabine is the current standard oral chemotherapy used in neoadjuvant concurrent chemoradiotherapy (NCCRT) for locally advanced rectal cancer (LARC) in North America. We compared the effectiveness of another oral chemotherapy agent, UFT (an oral combination of uracil and tegafur), to that of capecitabine. MATERIALS AND METHODS We identified LARC patients diagnosed from 200...

Journal: :Histology and histopathology 2007
H D Konstantinidis A C Sioga L D Economou K D Mpallas C I Demertzidis T T Pissanidou

BACKGROUND Neoadjuvant chemotherapy is a highly promising treatment modality for colorectal cancer. One of the basic side effects of this method is the possible impact on anastomotic healing. Capecitabine is a tumor selective pro-drug of 5-fluorouracil, indicated for the therapy of colorectal cancer. The aim of this study is to estimate the effect of perioperative Capecitabine administration on...

2012
R Bruno L Lindbom F Schaedeli Stark P Chanu F Gilberg N Frey L Claret

A phase II trial in metastatic breast cancer (MBC) (NO16853) failed to show noninferiority (progression-free survival, PFS) of capecitabine 825 mg/m(2) plus docetaxel 75 mg/m(2) to the registered capecitabine dose of 1,250 mg/m(2) plus docetaxel 75 mg/m(2). We developed a modeling framework based on NO16853 and the pivotal phase III MBC study, SO14999, to characterize the link between capecitab...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2013
Lee S Schwartzberg Kurt W Tauer Robert C Hermann Grace Makari-Judson Claudine Isaacs J Thaddeus Beck Virginia Kaklamani Edward J Stepanski Hope S Rugo Wei Wang Katherine Bell-McGuinn Jeffrey J Kirshner Peter Eisenberg Richard Emanuelson Mark Keaton Ellis Levine Diana C Medgyesy Rubina Qamar Alexander Starr Sunhee Kwon Ro Nathalie A Lokker Clifford A Hudis

PURPOSE We assessed adding the multikinase inhibitor sorafenib to gemcitabine or capecitabine in patients with advanced breast cancer whose disease progressed during/after bevacizumab. EXPERIMENTAL DESIGN This double-blind, randomized, placebo-controlled phase IIb study (ClinicalTrials.gov NCT00493636) enrolled patients with locally advanced or metastatic human epidermal growth factor recepto...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید